About
Technology
Issues
FAQ
Links
Official Page
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.